Cargando…
Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences
Paxlovid (nirmatrelvir plus ritonavir) is a new oral antiviral therapeutic for the treatment of COVID-19. Nirmatrelvir is an inhibitor of SARS-CoV-2 main protease, while ritonavir is used as a CYP3A inhibitor in low doses to slow the metabolism of nirmatrelvir, thus enhancing their therapeutic effec...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Sociedad Española de Quimioterapia
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333114/ https://www.ncbi.nlm.nih.gov/pubmed/35822605 http://dx.doi.org/10.37201/req/054.2022 |